Usman Zafar ParachaDateline: uzparacha
First Published: Oct 20, 2011 / Last Published: Jan 11, 2013
Usman Zafar Paracha has been blogging in science and technology for more than 6 years. He is CEO of SayPeople.com. Email: firstname.lastname@example.org Twitter: @jeepakistan
Usman Zafar Paracha's topics
Usman Zafar Paracha's claimed blogs
Usman Zafar Paracha's articles
July 7, 2012
Navistar Introduces New Pollution-Reducing Truck Tech
Navistar has introduced new technology for trucks to meet 2010 U.S. Environmental Protection Agency emissions regulations.
July 6, 2012
Unemployment Still at 8.2%, Only 80,000 New Jobs in June
Only 80,000 jobs have been added in June, representing a slowing trend in employment opportunities in the second quarter.
July 5, 2012
DARPA Calls for the Development of 2,000% More Efficient Robotic Systems
DARPA calls for scientific and engineering specialties to make 2,000% more efficient robots with good movement capabilities.
Vitamin D Useful in a Variety of Cases
Vitamin D is helpful against cancer, hip fractures and hospital acquired infections, and decreased healthcare costs.in Lifestyle
More Rescuers Improve Out-of-Hospital Cardiac Arrest Outcomes
Cardiopulmonary resuscitation by more people improve the chances of survival of out-of-hospital cardiac arrest patients.in Lifestyle
Volkswagen Will Acquire the Remaining 50.1% Porsche Stakes for $5.6 Billion
Volkswagen is finalizing the deal with Porsche by acquisition of the remaining 50.1% of stakes for $5.6 billion.
July 4, 2012
Quantum Computation at Room-Temperature for a Reasonable Time
Scientists have achieved quantum computation at room-temperature for nearly two seconds.
July 3, 2012
Mozilla’s Firefox OS Phones Would be Revealed in Early 2013
Mozilla has announced to reveal its Firefox OS phones early next year.
RIM CEO Heins Optimistic About Future
Thorsten Heins denies that Research in Motion Ltd. is in a "death spiral".
GSK Agrees to Resolve Healthcare Conflicts at the Expense of $3 Billion
GSK, British drug maker, agrees to pay $3 billion to resolve the conflicts of unapproved uses of its bestselling drugs.